Genmab bulks ADC pipeline with $1.8-billion purchase of ProfoundBio
2024-04-03
上市批准抗体药物偶联物临床2期并购临床1期
Genmab continued to expand its presence in the antibody-drug conjugate (ADC) field with a deal to buy ProfoundBio for $1.8 billion in cash. The transaction will give Genmab three clinical programmes, including the FRα-targeted, Topo1 ADC rinatabart sesutecan (Rina-S).
The therapy, also known as PRO1184, is currently in Phase II development for the treatment of ovarian cancer and other FRα-expressing solid tumoursFRα-expressing solid tumours. ProfoundBio’s pipeline also includes the CD70-targeted ADC PRO1160 and another dubbed PRO1107 that targets PTK7.
Jan van de Winkel, CEO of Genmab, noted that the purchase “firmly aligns with our long-term strategy,” adding that “ProfoundBio’s ADC candidates, proprietary technology platforms and talented team will be a great addition.” The transaction is expected to close this quarter.
Genmab already has an ADC partnership with Seagen, which produced the drug Tivdak (tisotumab vedotin-tftv) approved by the FDA in 2021 as a treatment for cervical cancer. The company also has a collaboration with ADC Therapeutics and another agreement with Synaffix for its ADC technologies.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。